Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC).
Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors.
(Lots of ASCO talk *next* week!)
